Can hydroxyzine cause QT interval prolongation and arrhythmias, particularly in elderly patients or those with pre‑existing cardiac disease, electrolyte disturbances, or concomitant QT‑prolonging medications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hydroxyzine and Cardiac Risk

Yes, hydroxyzine can cause QT interval prolongation and torsade de pointes (TdP), particularly in patients with underlying risk factors, and should be used with extreme caution or avoided entirely in elderly patients, those with pre-existing cardiac disease, electrolyte disturbances, or concomitant QT-prolonging medications. 1

FDA Warning and Mechanism

The FDA drug label explicitly warns that cases of QT prolongation and torsade de pointes have been reported during post-marketing use of hydroxyzine, with the majority occurring in patients with other risk factors for QT prolongation or TdP (pre-existing heart disease, electrolyte imbalances, or concomitant arrhythmogenic drug use). 1

Hydroxyzine blocks human ether-a-go-go-related gene (hERG) potassium channels in a concentration-dependent manner, the same mechanism responsible for QT prolongation with Class IA and III antiarrhythmic drugs. 2, 3 This inhibition of cardiac repolarization directly prolongs the QT interval and creates substrate for life-threatening arrhythmias. 2

High-Risk Patient Populations Requiring Extreme Caution

Hydroxyzine should be used with caution (or avoided) in patients with:

  • Congenital long QT syndrome or family history of long QT syndrome 1
  • Recent myocardial infarction, uncompensated heart failure, or bradyarrhythmias 1
  • Pre-existing heart disease or baseline QT prolongation 1, 2
  • Electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia) 1, 2
  • Elderly patients, who are more susceptible to sedation and cardiac effects 1
  • Complete atrioventricular block or significant bradycardia 4

The combination of cardiovascular disorders plus concomitant treatment with drugs known to induce arrhythmia represents the greatest combined risk factor for hydroxyzine-induced cardiac events. 2

Critical Drug Interactions

Caution is mandatory during concomitant use of drugs known to prolong the QT interval, including: 1

  • Class IA antiarrhythmics (quinidine, procainamide) 1
  • Class III antiarrhythmics (amiodarone, sotalol) 1
  • Certain antipsychotics (ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine) 1
  • Certain antidepressants (citalopram, fluoxetine) 1
  • Macrolide antibiotics (azithromycin, erythromycin, clarithromycin) 1
  • Fluoroquinolones (gatifloxacin, moxifloxacin) 1
  • Other QT-prolonging agents (pentamidine, methadone, ondansetron, droperidol) 1

Clinical Evidence of Harm

Real-world pharmacovigilance data identified 59 reports of QT prolongation and/or TdP potentially linked to hydroxyzine use between 1955 and 2016. 2 Aside from intentional overdose, all cases involved underlying medical conditions or concomitant medications that constituted at least one additional risk factor. 2

Case reports document TdP occurring even with small doses (12.5 mg) in high-risk patients, such as an 82-year-old woman with complete atrioventricular block who developed TdP during pacemaker implantation after hydroxyzine administration for sedation. 4 Another case involved a 58-year-old male with an ICD who developed refractory TdP after receiving 50 mg hydroxyzine for opioid withdrawal symptoms. 5

A particularly instructive case involved a 34-year-old woman with an undiagnosed HERG mutation who experienced repetitive syncope after taking 75 mg hydroxyzine for several days, with QTc prolonging to 630 ms. 3 The QTc shortened to 464 ms after drug cessation, demonstrating the direct causal relationship. 3

Risk Classification

Based on pharmacovigilance analysis and electrophysiological studies, hydroxyzine is appropriately listed as a drug with "conditional risk of TdP", meaning the risk is substantially elevated in patients with underlying risk factors. 2 This classification aligns with American Heart Association guidance that distinguishes between high-risk drugs (which may cause TdP even without additional risk factors) and conditional-risk drugs (which require other risk factors to manifest arrhythmia). 6

Clinical Recommendations

Before prescribing hydroxyzine:

  • Obtain baseline ECG to measure QTc interval, particularly in elderly patients or those with cardiac risk factors 6, 1
  • Check and correct electrolyte abnormalities (maintain potassium 4.5-5.0 mEq/L, magnesium >2.0 mg/dL) 6
  • Review all concomitant medications for QT-prolonging potential 1
  • Consider alternative agents in patients with baseline QTc >450 ms (men) or >470 ms (women) 7

During hydroxyzine therapy:

  • Use the lowest effective dose 5
  • Monitor for symptoms of arrhythmia (palpitations, dizziness, syncope) 8
  • Discontinue immediately if QTc exceeds 500 ms or increases >60 ms from baseline 9

Common Pitfalls to Avoid

The most dangerous pitfall is administering hydroxyzine to elderly patients with multiple cardiac risk factors without ECG screening. 1 The sedating properties may mask early warning symptoms of arrhythmia in this population. 1

Another critical error is combining hydroxyzine with other QT-prolonging medications (particularly macrolide antibiotics, antipsychotics, or antiarrhythmics) without cardiac monitoring. 1, 2

Never assume that low doses are safe in high-risk patients—case reports document TdP with doses as low as 12.5 mg in patients with bradycardia or conduction abnormalities. 4

References

Guideline

Comparative Risk of QT Prolongation and Torsades de Pointes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Drug induced QT prolongation].

Wiener klinische Wochenschrift, 2008

Related Questions

What are the cardiac effects of Hydroxyzine (Atarax)?
Can hydroxyzine pamoate be used to treat palpitations?
Is hydroxyzine (an antihistamine) safe to use in patients with prolonged QTc (corrected QT interval) interval?
In a young male patient taking hydroxyzine, sertraline, and quetiapine with a QTc of 453 ms, normal electrolytes and pending magnesium results, should hydroxyzine be discontinued immediately?
In a patient with a QTc of 453 ms who is taking hydroxyzine, sertraline, and quetiapine, and has no additional risk factors or symptoms, should I discontinue hydroxyzine while awaiting electrolyte results?
Can statin therapy cause elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in a patient with a normal FibroScan, normal autoimmune hepatitis panel, elevated γ‑glutamyl transferase (GGT), and reported alcohol use?
What is the appropriate evaluation and management for a 1‑year‑old child with an elevated monocyte count?
What is the most likely diagnosis and appropriate emergency management for a patient with epigastric pain, three episodes of vomiting, obstipation for three days (but passed flatus three times yesterday), hyperactive bowel sounds and no abdominal rigidity?
What are the maximum single‑dose limits and maximum weekly dosing frequencies for intravenous iron preparations (iron sucrose [Venofer], ferric gluconate [Ferrlecit], low‑molecular‑weight iron dextran [INFeD/Dexferrum], ferric carboxymaltose [Ferinject/Injectafer], ferumoxytol [Feraheme])?
Which vitamin or mineral supplements are contraindicated when taking doxycycline?
When obtaining blood cultures and an arterial blood gas sample, which should be drawn first, and should the aerobic bottle be filled before the anaerobic bottle?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.